JP2007526302A - 高性能タンジェンシャルフローフィルトレーションを用いるタンパク質分画方法 - Google Patents
高性能タンジェンシャルフローフィルトレーションを用いるタンパク質分画方法 Download PDFInfo
- Publication number
- JP2007526302A JP2007526302A JP2007501797A JP2007501797A JP2007526302A JP 2007526302 A JP2007526302 A JP 2007526302A JP 2007501797 A JP2007501797 A JP 2007501797A JP 2007501797 A JP2007501797 A JP 2007501797A JP 2007526302 A JP2007526302 A JP 2007526302A
- Authority
- JP
- Japan
- Prior art keywords
- membrane
- feed stream
- filtration
- milk
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000009295 crossflow filtration Methods 0.000 title claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 title claims description 159
- 102000004169 proteins and genes Human genes 0.000 title claims description 148
- 238000005194 fractionation Methods 0.000 title claims description 41
- 238000000034 method Methods 0.000 claims abstract description 251
- 239000012528 membrane Substances 0.000 claims abstract description 223
- 235000013336 milk Nutrition 0.000 claims abstract description 128
- 239000008267 milk Substances 0.000 claims abstract description 128
- 210000004080 milk Anatomy 0.000 claims abstract description 128
- 230000008569 process Effects 0.000 claims abstract description 121
- 230000009261 transgenic effect Effects 0.000 claims abstract description 27
- 238000001914 filtration Methods 0.000 claims description 100
- 239000012466 permeate Substances 0.000 claims description 81
- 239000012465 retentate Substances 0.000 claims description 67
- 238000000108 ultra-filtration Methods 0.000 claims description 62
- 238000011026 diafiltration Methods 0.000 claims description 54
- 230000004907 flux Effects 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 claims description 40
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 claims description 40
- 239000000706 filtrate Substances 0.000 claims description 39
- 102000046101 human AFP Human genes 0.000 claims description 39
- 239000000243 solution Substances 0.000 claims description 38
- 238000000746 purification Methods 0.000 claims description 36
- 239000011148 porous material Substances 0.000 claims description 29
- 241000894007 species Species 0.000 claims description 29
- 239000000919 ceramic Substances 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 230000007704 transition Effects 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 229960000074 biopharmaceutical Drugs 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 239000003929 acidic solution Substances 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 229940072221 immunoglobulins Drugs 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 239000013592 cell lysate Substances 0.000 claims description 2
- 239000012670 alkaline solution Substances 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 239000007975 buffered saline Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 238000004064 recycling Methods 0.000 claims 1
- 238000004140 cleaning Methods 0.000 abstract description 28
- 239000000203 mixture Substances 0.000 abstract description 14
- 239000005018 casein Substances 0.000 abstract description 12
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract description 12
- 235000021240 caseins Nutrition 0.000 abstract description 12
- 241000894006 Bacteria Species 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 7
- 239000000693 micelle Substances 0.000 abstract description 5
- 239000013618 particulate matter Substances 0.000 abstract description 5
- 238000013386 optimize process Methods 0.000 abstract 1
- 238000011146 sterile filtration Methods 0.000 abstract 1
- 238000001471 micro-filtration Methods 0.000 description 124
- 235000018102 proteins Nutrition 0.000 description 120
- 239000000047 product Substances 0.000 description 56
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 239000012530 fluid Substances 0.000 description 24
- 230000000717 retained effect Effects 0.000 description 23
- 108010011756 Milk Proteins Proteins 0.000 description 21
- 102000014171 Milk Proteins Human genes 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 20
- 108010076119 Caseins Proteins 0.000 description 19
- 235000021239 milk protein Nutrition 0.000 description 19
- 102000011632 Caseins Human genes 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 238000012545 processing Methods 0.000 description 17
- 238000000926 separation method Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 239000012141 concentrate Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 238000005086 pumping Methods 0.000 description 11
- 238000011084 recovery Methods 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 241000283707 Capra Species 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000013365 dairy product Nutrition 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000005457 optimization Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 239000000356 contaminant Substances 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 230000010287 polarization Effects 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 238000001542 size-exclusion chromatography Methods 0.000 description 7
- 239000012510 hollow fiber Substances 0.000 description 6
- 238000001155 isoelectric focusing Methods 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 102000004407 Lactalbumin Human genes 0.000 description 5
- 108090000942 Lactalbumin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000008192 Lactoglobulins Human genes 0.000 description 4
- 108010060630 Lactoglobulins Proteins 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000011070 membrane recovery Methods 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 3
- 101000693922 Bos taurus Albumin Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000006651 lactation Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 239000008234 soft water Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000021241 α-lactalbumin Nutrition 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001450 anions Chemical group 0.000 description 2
- 238000011021 bench scale process Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical group 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 238000004262 preparative liquid chromatography Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000010977 unit operation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 235000021247 β-casein Nutrition 0.000 description 2
- 108050001786 Alpha-s2 casein Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101000946377 Bos taurus Alpha-lactalbumin Proteins 0.000 description 1
- 101000741065 Bos taurus Beta-casein Proteins 0.000 description 1
- 101001008231 Bos taurus Beta-lactoglobulin Proteins 0.000 description 1
- 101000761239 Bos taurus Kappa-casein Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000693913 Homo sapiens Albumin Proteins 0.000 description 1
- 101000920778 Homo sapiens DNA excision repair protein ERCC-8 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- -1 IgG1 antibodies Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 101000895752 Rattus norvegicus Alpha-S2-casein-like A Proteins 0.000 description 1
- 101000947125 Rattus norvegicus Beta-casein Proteins 0.000 description 1
- 101000667278 Rattus norvegicus Whey acidic protein Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 101710087237 Whey acidic protein Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000011101 absolute filtration Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005112 continuous flow technique Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000012538 diafiltration buffer Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000048696 human ERCC8 Human genes 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000013541 low molecular weight contaminant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000010327 methods by industry Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001254 nonsecretory effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000011860 particles by size Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012451 transgenic animal system Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000004148 unit process Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/147—Microfiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/16—Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/58—Multistep processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/02—Inorganic material
- B01D71/024—Oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/10—Cross-flow filtration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/16—Diafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55013704P | 2004-03-04 | 2004-03-04 | |
| US11/051,216 US20050197496A1 (en) | 2004-03-04 | 2005-02-04 | Methods of protein fractionation using high performance tangential flow filtration |
| PCT/US2005/004332 WO2005091801A2 (en) | 2004-03-04 | 2005-02-08 | Methods of protein fractionation using high performance tangential flow filtration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007526302A true JP2007526302A (ja) | 2007-09-13 |
| JP2007526302A5 JP2007526302A5 (enExample) | 2008-03-27 |
Family
ID=34914815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501797A Abandoned JP2007526302A (ja) | 2004-03-04 | 2005-02-08 | 高性能タンジェンシャルフローフィルトレーションを用いるタンパク質分画方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050197496A1 (enExample) |
| EP (1) | EP1732587A4 (enExample) |
| JP (1) | JP2007526302A (enExample) |
| KR (1) | KR20060129530A (enExample) |
| AU (1) | AU2005227064A1 (enExample) |
| CA (1) | CA2560930A1 (enExample) |
| IL (1) | IL177877A0 (enExample) |
| WO (1) | WO2005091801A2 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012210187A (ja) * | 2011-03-31 | 2012-11-01 | Kaneka Corp | 細胞懸濁液の濃縮方法 |
| JP2016511238A (ja) * | 2013-02-01 | 2016-04-14 | アンピオ ファーマシューティカルズ，インコーポレイテッド | ジケトピペラジンおよびジケトピペラジン含有組成物を生産するための方法 |
| JP2017510452A (ja) * | 2014-03-07 | 2017-04-13 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | 生物学的生成物の分画のための装置及び方法 |
| JP2021527564A (ja) * | 2018-06-21 | 2021-10-14 | サイティバ・スウェーデン・アクチボラグ | ろ過のためのシステムおよび関連する方法 |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030005468A1 (en) * | 1998-06-19 | 2003-01-02 | Meade Harry M. | Methods and vectors for improving nucleic acid expression |
| US20040226053A1 (en) * | 2000-10-13 | 2004-11-11 | Meade Harry M. | Methods of producing a target molecule in a transgenic animal and purification of the target molecule |
| NZ588616A (en) | 2004-09-30 | 2012-05-25 | Bayer Healthcare Llc | An apparatus for separating a protein of interest comprising a purification system integrated with a particle removal system |
| US20060130159A1 (en) * | 2004-12-09 | 2006-06-15 | Nick Masiello | Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum |
| US7531632B2 (en) * | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
| WO2007103971A2 (en) * | 2006-03-07 | 2007-09-13 | Throwleigh Technologies, L.L.C. | Diafiltration system to fractionate protein mixtures |
| EP2014760A1 (en) * | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
| CN101754977B (zh) * | 2007-07-17 | 2013-07-17 | 弗·哈夫曼-拉罗切有限公司 | 可变切向流过滤 |
| BRPI0919998A2 (pt) * | 2008-10-30 | 2017-06-06 | Paques Ip Bv | método para a filtração de um líquido de biorreator, módulo de membrana de fluxo cruzado, sistema de biorreator de membrana, e, uso de um fluxo descendente de líquido de um líquido de biorreator |
| US9055752B2 (en) | 2008-11-06 | 2015-06-16 | Intercontinental Great Brands Llc | Shelf-stable concentrated dairy liquids and methods of forming thereof |
| US20120029165A1 (en) * | 2010-07-16 | 2012-02-02 | Etzel Mark R | Methods and Compositions Involving Whey Protein Isolates |
| UA112972C2 (uk) | 2010-09-08 | 2016-11-25 | Інтерконтінентал Грейт Брендс ЛЛС | Рідкий молочний концентрат з високим вмістом сухих речовин |
| AU2011350895B2 (en) | 2010-12-30 | 2015-05-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Glycols as pathogen inactivating agents |
| EP3594230A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| BR112015019348A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária |
| ES2842350T3 (es) * | 2013-03-19 | 2021-07-13 | Cmc Biologics As | Un procedimiento para la producción de un producto (por ejemplo, polipéptido) en un proceso de fermentación de cultivo celular continuo |
| MX384222B (es) | 2013-07-05 | 2025-03-14 | Lab Francais Du Fractionnement | Matriz de cromatografia de afinidad. |
| CA3140009C (en) | 2014-05-13 | 2023-09-05 | Amgen Inc. | Process control systems and methods for use with filters and filtration processes |
| CN114797474A (zh) * | 2014-05-21 | 2022-07-29 | 非链实验室 | 用于缓冲溶液交换的系统和方法 |
| US10207225B2 (en) | 2014-06-16 | 2019-02-19 | Emd Millipore Corporation | Single-pass filtration systems and processes |
| WO2015195453A2 (en) | 2014-06-16 | 2015-12-23 | Emd Millipore Corporation | Methods for increasing the capacity of flow-through processes |
| US10399039B2 (en) | 2014-06-25 | 2019-09-03 | Emd Millipore Corporation | Compact spiral-wound filter elements, modules and systems |
| CN105745009B (zh) | 2014-08-29 | 2018-09-28 | Emd 密理博公司 | 单程切向流过滤系统和具有渗余物的再循环的切向流过滤系统 |
| EP4147769B1 (en) | 2014-08-29 | 2025-05-21 | EMD Millipore Corporation | Processes for filtering liquids using single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate |
| DE102015108501A1 (de) * | 2015-05-29 | 2016-12-01 | Sartorius Stedim Biotech Gmbh | Verfahren und Filtrationsvorrichtung zur Herstellung einer konzentrierten Produktlösung |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| CA3023486C (en) | 2016-06-09 | 2022-03-29 | Emd Millipore Corporation | Radial-path filter elements, systems and methods of using same |
| CN108017689A (zh) * | 2016-11-04 | 2018-05-11 | 郑州伊美诺生物技术有限公司 | 一种离心管及使用该离心管获取抗体蛋白的方法 |
| CN106474466B (zh) * | 2016-12-07 | 2018-04-13 | 申联生物医药（上海）股份有限公司 | 一种口蹄疫疫苗的制备方法 |
| WO2019173752A1 (en) | 2018-03-08 | 2019-09-12 | Repligen Corporation | Tangential flow depth filtration systems and methods of filtration using same |
| KR102819571B1 (ko) | 2018-05-25 | 2025-06-12 | 리플리겐 코포레이션 | 접선 유동 여과 시스템 및 방법 |
| WO2021030573A1 (en) * | 2019-08-13 | 2021-02-18 | Repligen Corporation | Control systems and methods for automated clarification of cell culture with high solids content |
| CN113559712A (zh) * | 2020-04-29 | 2021-10-29 | 上海药明生物技术有限公司 | 切向流过滤系统与方法 |
| JP7695344B2 (ja) | 2021-05-21 | 2025-06-18 | ケンブリッジ クロップス インコーポレイテッド． ドゥーイングビジネスアズ モリ | 絹フィブロイン溶液及び絹フィブロインを含む粉末を製造するためのシステム及び方法 |
| US11864569B2 (en) | 2021-08-16 | 2024-01-09 | Cambridge Crops, Inc. | Systems and methods for improving the performance of cereal using a silk fibroin solution and powders containing silk fibroin |
| EP4299156A1 (en) * | 2022-06-29 | 2024-01-03 | Sartorius Stedim Biotech GmbH | Tangential flow filtration/chromatography systems, use thereof, and methods of separation |
| FR3139999A1 (fr) * | 2022-09-22 | 2024-03-29 | Bucher Vaslin | Procédé de gestion du colmatage de membrane d’un dispositif de filtration tangentiel |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3519558A (en) * | 1968-02-15 | 1970-07-07 | Abcor Inc | Separation of similar solutes using a semipermeable membrane |
| BE759625A (fr) * | 1969-12-10 | 1971-04-30 | Molkereigenossenschaft Dahlenb | Procede et dispositif pour la dialyse du lait, en particulier pour l'obtention de l'albumine du lait et du petit-lait |
| CH566798A5 (enExample) * | 1973-05-29 | 1975-09-30 | Battelle Memorial Institute | |
| SE396017B (sv) * | 1974-12-23 | 1977-09-05 | Alfa Laval Ab | Filtreringsforfarande, serskilt for ultrafiltrering |
| US4351710A (en) * | 1980-01-10 | 1982-09-28 | Ionics, Incorporated | Fractionation of protein mixtures |
| US4350156A (en) * | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
| JPS583705B2 (ja) * | 1980-07-18 | 1983-01-22 | 川澄化学工業株式会社 | 二重ロ過型血漿分離交換装置 |
| US4420398A (en) * | 1981-08-13 | 1983-12-13 | American National Red Cross | Filteration method for cell produced antiviral substances |
| US4888115A (en) * | 1983-12-29 | 1989-12-19 | Cuno, Incorporated | Cross-flow filtration |
| DE3432718C1 (de) * | 1984-09-06 | 1986-05-22 | Biotest Pharma GmbH, 6000 Frankfurt | Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen |
| US4874516A (en) * | 1984-12-29 | 1989-10-17 | Ngk Insulators, Ltd. | A ceramic filter for semi-ultrafiltration |
| US4789482A (en) * | 1986-02-10 | 1988-12-06 | Millipore Corporation | Method for separating liquid compositions on the basis of molecular weight |
| EP0287513B1 (en) * | 1987-04-11 | 1992-12-02 | Ciba-Geigy Ag | An isoelectric focusing process and a means for carrying out said process |
| US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5750172A (en) * | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5948441A (en) * | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
| US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5256294A (en) * | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
| US5356651A (en) * | 1992-12-30 | 1994-10-18 | Pall Corporation | Manufacturing method for producing sterile milk using dynamic microfiltration |
| EP0804070B1 (en) * | 1993-03-09 | 2000-05-24 | Genzyme Corporation | Process of isolation of proteins from milk |
| US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5518624A (en) * | 1994-05-06 | 1996-05-21 | Illinois Water Treatment, Inc. | Ultra pure water filtration |
| US5585466A (en) * | 1994-12-06 | 1996-12-17 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Crystals of serum albumin for use in genetic engineering and rational drug design |
| US5843705A (en) * | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| US5597486A (en) * | 1995-05-01 | 1997-01-28 | Millipore Investment Holdings Limited | Membrane filtration with optimized addition of second liquid to maximize flux |
| WO1997009350A1 (en) * | 1995-09-07 | 1997-03-13 | Ppl Therapeutics (Scotland) Ltd. | Purification of alpha-1 proteinase inhibitor |
| US6054051A (en) * | 1996-01-17 | 2000-04-25 | Genentech, Inc. | Tangential-flow filtration system |
| US6268487B1 (en) * | 1996-05-13 | 2001-07-31 | Genzyme Transgenics Corporation | Purification of biologically active peptides from milk |
| US5945577A (en) * | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| AP1219A (en) * | 1997-10-20 | 2003-10-22 | Gtc Biotherapeutics Inc | Novel modified MSP-1 nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems. |
| FR2787465A1 (fr) * | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
| US6984378B1 (en) * | 1999-02-26 | 2006-01-10 | Pfizer, Inc. | Method for the purification, recovery, and sporulation of cysts and oocysts |
| US7544500B2 (en) * | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
| KR100788093B1 (ko) * | 2002-04-26 | 2007-12-21 | 제넨테크, 인크. | 단백질의 비친화성 정제 |
| US7264728B2 (en) * | 2002-10-01 | 2007-09-04 | Dow Corning Corporation | Method of separating components in a sample using silane-treated silica filter media |
| US20040162414A1 (en) * | 2002-11-22 | 2004-08-19 | Santora Ling C. | Method for reducing or preventing modification of a polypeptide in solution |
| RU2005129745A (ru) * | 2003-02-24 | 2006-03-20 | Джитиси Байотерапьютикс, Инк. (Us) | Способы и устройство проточной фильтрации вдоль потока |
| US20060130159A1 (en) * | 2004-12-09 | 2006-06-15 | Nick Masiello | Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum |
-
2005
- 2005-02-04 US US11/051,216 patent/US20050197496A1/en not_active Abandoned
- 2005-02-08 JP JP2007501797A patent/JP2007526302A/ja not_active Abandoned
- 2005-02-08 EP EP05713340A patent/EP1732587A4/en not_active Withdrawn
- 2005-02-08 WO PCT/US2005/004332 patent/WO2005091801A2/en not_active Ceased
- 2005-02-08 KR KR1020067020867A patent/KR20060129530A/ko not_active Withdrawn
- 2005-02-08 CA CA002560930A patent/CA2560930A1/en not_active Abandoned
- 2005-02-08 AU AU2005227064A patent/AU2005227064A1/en not_active Abandoned
-
2006
- 2006-09-04 IL IL177877A patent/IL177877A0/en unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012210187A (ja) * | 2011-03-31 | 2012-11-01 | Kaneka Corp | 細胞懸濁液の濃縮方法 |
| JP2016511238A (ja) * | 2013-02-01 | 2016-04-14 | アンピオ ファーマシューティカルズ，インコーポレイテッド | ジケトピペラジンおよびジケトピペラジン含有組成物を生産するための方法 |
| JP2017510452A (ja) * | 2014-03-07 | 2017-04-13 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | 生物学的生成物の分画のための装置及び方法 |
| JP2021527564A (ja) * | 2018-06-21 | 2021-10-14 | サイティバ・スウェーデン・アクチボラグ | ろ過のためのシステムおよび関連する方法 |
| US11717790B2 (en) | 2018-06-21 | 2023-08-08 | Cytiva Sweden Ab | System for filtration and associated method |
| JP7387651B2 (ja) | 2018-06-21 | 2023-11-28 | サイティバ・スウェーデン・アクチボラグ | ろ過のためのシステムおよび関連する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005227064A1 (en) | 2005-10-06 |
| US20050197496A1 (en) | 2005-09-08 |
| EP1732587A4 (en) | 2007-09-05 |
| CA2560930A1 (en) | 2005-10-06 |
| IL177877A0 (en) | 2006-12-31 |
| KR20060129530A (ko) | 2006-12-15 |
| WO2005091801A3 (en) | 2006-06-15 |
| WO2005091801A2 (en) | 2005-10-06 |
| EP1732587A2 (en) | 2006-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007526302A (ja) | 高性能タンジェンシャルフローフィルトレーションを用いるタンパク質分画方法 | |
| US20040167320A1 (en) | Methods of tangential flow filtration and an apparatus therefore | |
| DK1991063T3 (en) | CLEARING TRANSGEN MILK USING DEPTH FILTERING | |
| CA2254871C (en) | Purification of biologically active peptides from milk | |
| CN101076347B (zh) | 用于集成连续生产生物分子的装置和方法 | |
| US6214221B1 (en) | Method and apparatus for purification of biological substances | |
| Arunkumar et al. | Investigation of single-pass tangential flow filtration (SPTFF) as an inline concentration step for cell culture harvest | |
| Madsen et al. | Single pass tangential flow filtration: Critical operational variables, fouling, and main current applications | |
| JP7174072B2 (ja) | タンパク質抽出方法およびシステム | |
| JP7737374B2 (ja) | 透析濾過緩衝液を用いて増強したウイルス濾過 | |
| CA2495890A1 (en) | Model for microfiltration of poly-disperse suspensions | |
| CN101027080A (zh) | 用高效切向流过滤进行蛋白质分级的方法 | |
| KR20210093304A (ko) | 결합 및 용리 크로마토그래피 정제의 부피 부하 유량을 감소시키고 생산성을 증가시키기 위한 인-라인 생성물 농축 | |
| Ulber et al. | Membranes for protein isolation and purification | |
| WO2025133047A1 (en) | System and methods for counter-current filtration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080208 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080208 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20100203 |